BioCentury | Apr 8, 2021
Distillery Therapeutics

Camptothecin-carrying bioadhesive nanoparticles for skin cancer

...Writer DISEASE CATEGORY: CancerINDICATION: Skin cancerA Yale University team showed that bioadhesive nanoparticle delivery of topoisomerase...
...Acad. Sci. USA; published online Feb. 16, 2021doi:10.1073/pnas.2020575118CONTACT: Michael Girardi, Yale University, New Haven, Conn.email: michael.girardi@yale.edu Claire Quang Yale University Topoisomerase Cancer Skin...
BioCentury | Jul 27, 2020
Deals

AZ goes early for its latest $1B ADC deal with Daiichi

...superfamily member 17 HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 TOP1 - Topoisomerase...
BioCentury | Apr 29, 2020
Emerging Company Profile

Bugworks: breaking the U.S.-centric antimicrobial mold

...not eject. Once they enter the bacteria, the Gyrox antibiotics disrupt DNA replication by inhibiting topoisomerase...
BioCentury | Apr 15, 2020
Emerging Company Profile

Backed by Third Rock-led syndicate, MOMA seeks new ATP-powered targets by interrogating 'molecular machines'

...CEO: Reid Huber Patents: Undisclosed Targets CFTR - Cystic fibrosis transmembrane conductance regulator TOP2 - Topoisomerase...
BioCentury | Jan 1, 2020
Company News

Fewer FDA approvals in 2019, but a basket of firsts

...3-kinase α PRR4 - Nectin-4 ROS1 - c-ros proto-oncogene 1 receptor tyrosine kinase TOP1 - Topoisomerase...
BioCentury | Dec 21, 2019
Company News

Efficacy data set trastuzumab ADC up for fast approval for third-line breast cancer

...HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2; PRR4 - Nectin-4; TOP1 - Topoisomerase...
...DS-8201, DS-8201a) Daiichi Sankyo Co. Ltd. [MERGED] AstraZeneca plc AstraZeneca plc Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) Topoisomerase...
BioCentury | Dec 12, 2019
Company News

Dec. 11 Company Quick Takes: Kite, Alkermes, argenx, Reblozyl, Denovo-Sunesis

...in AML. Financial terms are undisclosed. Targets: ACVR2B - Activin receptor type 2B; TOP2 - Topoisomerase...
BioCentury | Dec 11, 2019
Clinical News

AstraZeneca, Daiichi’s trastuzumab ADC sets new efficacy bar in breast cancer

...of Medicine. Targets HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2; TOP1 - Topoisomerase...
BioCentury | Oct 29, 2019
Company News

Oct. 28 Company Quick Takes: MOR106 dropped in atopic dermatitis; plus Blueprint, Merus, Gilead-Glympse, Heron and GSK

...structure infections and gonorrhea. Initial data are expected by YE21. Gepotidacin is a triazaacenaphthylene bacterial topoisomerase...
BioCentury | Oct 19, 2019
Company News

Oct. 18 Company Quick Takes: AZ-Daiichi, Sanofi, Merck, Lilly and AFTD-Target ALS

...and FTD. Targets: HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2; TOP1 - Topoisomerase...
...and Co. Target ALS Foundation Daiichi Pharmaceutical Co. Ltd. AstraZeneca plc Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) Topoisomerase...
Items per page:
1 - 10 of 1019